The 12 genes included ARID1A, ARID1B, BRIP1, NOTCH2, NOTCH4, EPHA5, ROS1, FAT1, SPEN, NSD1, PTPRT, and ZFHX3. Among them, only the mutation of ZFHX3 was associated with better OS in another pan-cancer cohort [MSKCC-Zehir cohort (13)] not receiving the ICB therapy (P = 0.007) (Supplementary Figure 1). This evidence concerns the gene NOTCH2 and cancer.